Jack Hoadley, PhD. is a research professor at Georgetown University’s Health Policy Institute. There he directs research projects on health financing topics, including Medicare and Medicaid.

Recent Posts by Jack Hoadley

How Could a New Administration Tackle Affordable Care Act Challenges? Look to Medicare

How government officials responded to the Medicare Advantage crisis could hold lessons for policymakers’ response to developments in the ACA’s marketplaces. What were the key policy solutions?

November 7, 2016Following the ACA, Medicare

The Cost Of A Cure: Revisiting Medicare Part D And Hepatitis C Drugs

Using new data released by CMS, we consider both the ongoing impact of hepatitis C drugs for Part D and the broader implications for Medicare of new high-priced drugs entering the market.

November 3, 2016Drugs and Medical Innovation, Medicare

Medicaid Expansion: Driving Innovation In Behavioral Health Integration

The Medicaid expansion is playing a critical role in driving integration and improvement in behavioral health care. Two provider systems in Kentucky and Nevada illustrate some of the innovative approaches that improve the quality of behavioral health care at safety-net institutions.

The Ripple Effects Of Medicaid Expansion

Residents of Medicaid expansion states are more likely to have insurance and thus more likely to have a usual source of care; they are less likely to have unmet health care needs or problems paying medical bills. But there are further benefits of Medicaid expansion.

President Obama’s Budget Takes State-Level Debates Over Surprise Out-of-Network Bills To National Policymakers

President Obama’s final budget proposal was met with a lot of political opposition. However, one legislative proposal, aimed at helping consumers who get stuck with surprise bills from out-of-network health care providers, deserves attention.

The Cost Of A Cure: Medicare’s Role In Treating Hepatitis C

For a patient with hepatitis C, a potentially deadly disease, the prospect of finding a cure with minimal side effects is a really big deal. Also a big deal is the cost of Sovaldi (sofosbuvir), an oral drug approved by the Food and Drug Administration in December 2013 for the treatment of...

Assessing A CMS Proposal To Improve Competition Among Medicare Part D Drug Plans

In one provision of its January Notice of Proposed Rulemaking (NPRM), for Medicare Part D and Medicare Advantage, CMS proposed that it will accept no more than two stand-alone prescription drug plan (PDP) bids from each Part D plan sponsor, starting in coverage year 2016. The agency stated two...

The Medicare Part D Drug Rebate Proposal: Rebutting An Unpersuasive Critique

A proposal to require manufacturers to pay a minimum rebate on drugs covered under Medicare Part D for those beneficiaries who receive the program’s Low-Income Subsidy (LIS) has received considerable attention during the current debate over the federal budget. Through mandating discounts in...